Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study 94 patients enrolled out of 102 planned across Korea and the U.S. Interim baseline characteristics to be presented at the 2025 KATRD International Conference SEOUL, South Korea, Oct. 27, 2025 /PRNewswire/ — Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) announced that… Continue reading Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial
Tag: Financial Results
Keurig Dr Pepper Reports Q3 2025 Results, Raises Full Year Net Sales Outlook and Reaffirms EPS Guidance for 2025
Q3 Results Driven by Strong Top-Line Growth Continued Momentum in U.S. Refreshment Beverages and Improving U.S. Coffee Trends Company Raises 2025 Constant Currency Net Sales Outlook and Reaffirms Adjusted EPS Guidance BURLINGTON, Mass. and FRISCO, Texas, Oct. 27, 2025 /PRNewswire/ — Keurig Dr Pepper Inc. (NASDAQ: KDP) today reported results for the third quarter of… Continue reading Keurig Dr Pepper Reports Q3 2025 Results, Raises Full Year Net Sales Outlook and Reaffirms EPS Guidance for 2025
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
DUBLIN, Oct. 27, 2025 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST / 10:00 pm GMT) that day. Conference… Continue reading Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
West Synchrony™ Prefillable Syringe System Launches at CPHI: Redefining a system-level solution for drug delivery
The West Synchrony PFS system delivers a fully verified system-level solution designed specifically for biologics and vaccines. It sets a new standard in drug delivery by accelerating syringe selection through its comprehensive performance and regulatory data packages. “Leaders in drug development face pressures to meet milestones efficiently amid complex challenges, amongst them, selecting prefillable syringes.… Continue reading West Synchrony™ Prefillable Syringe System Launches at CPHI: Redefining a system-level solution for drug delivery
Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek® 2025
-Multiple posters being presented on Ascletis’ small molecule and peptide obesity programs -Full analysis of 28-day multiple ascending dose study of oral GLP-1R small molecule agonist ASC30 as a late-breaking poster as well as ASC30 once-monthly treatment formulation and once-quarterly maintenance formulation HONG KONG, Oct. 27, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”)… Continue reading Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek® 2025
Implantica presents the third quarter 2025 on October 31 at 15:00 CET
VADUZ, Liechtenstein, Oct. 27, 2025 /PRNewswire/ — Implantica AG (publ) invites investors to a presentation of the third quarter 2025 at 15:00 CET on October 31. The interim report for the third quarter will be published at 8:00 a.m. CET on the same day. The presentation will be in English via a webcast with teleconference:… Continue reading Implantica presents the third quarter 2025 on October 31 at 15:00 CET
JHX Investors Have Opportunity to Join James Hardie Industries plc Fraud Investigation with the Schall Law Firm
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of James Hardie Industries plc (“James Hardie” or “the Company”) (NYSE: JHX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading… Continue reading JHX Investors Have Opportunity to Join James Hardie Industries plc Fraud Investigation with the Schall Law Firm
Zions Bancorporation, N.A. Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights – ZION
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ — The DJS Law Group announces that it is investigating claims on behalf of investors of Zions Bancorporation, N.A. (“Zions Bancorp” or “the Company”) (NASDAQ: ZION) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent… Continue reading Zions Bancorporation, N.A. Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights – ZION
ZION Investors Have Opportunity to Join Zions Bancorporation, N.A. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zions Bancorporation, N.A. (“Zions Bancorp” or “the Company”) (NASDAQ: ZION) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements… Continue reading ZION Investors Have Opportunity to Join Zions Bancorporation, N.A. Fraud Investigation with the Schall Law Firm
Vera Bradley, Inc. Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights – VRA
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ — The DJS Law Group announces that it is investigating claims on behalf of investors of Vera Bradley, Inc. (“Vera Bradley” or “the Company”) (NASDAQ: VRA) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent… Continue reading Vera Bradley, Inc. Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights – VRA